Quinolines (including Hydrogenated) Patents (Class 514/311)
-
Patent number: 9717702Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.Type: GrantFiled: January 12, 2016Date of Patent: August 1, 2017Assignee: IO Therapeutics, Inc.Inventor: Roshantha A. Chandraratna
-
Patent number: 9717746Abstract: Synthetic ether alkyl-lysophospholipids (APLs) provide an effective treatment for subjects suffering from cholinergic seizures. Among other uses, APLs may be used to treat the effects of epileptic seizures in particular cholinergic seizures caused by exposure to insecticides or chemical warfare nerve agent exposure. Edelfosine, an APL, has been show to be particularly effective in these areas.Type: GrantFiled: December 16, 2014Date of Patent: August 1, 2017Inventor: Peter Andrew Ferchmin
-
Patent number: 9714238Abstract: This invention provides well defined 6-alkyl or hydroxyalkyl-1-naphthamide or quinoline compounds for treating glaucoma or ocular hypertension.Type: GrantFiled: December 20, 2013Date of Patent: July 25, 2017Assignee: ALLERGAN, INC.Inventor: David W. Old
-
Patent number: 9701627Abstract: Compounds, and methods of using the same, are provided as therapies for the treatment leucine-rich repeat kinase-2 (LRRK2)-related disorders including, but not limited to, neurodegenerative and neuroinflammatory disorders, such as Parkinson's Disease.Type: GrantFiled: June 16, 2015Date of Patent: July 11, 2017Assignee: UNIVERSITY OF MARYLAND, BALTIMOREInventors: Wanli Smith, Fengtian Xue, Alexander D MacKerell, Jr.
-
Patent number: 9655872Abstract: A method of treating cancer is disclosed comprising administering to a patient in need of such treatment a RXR agonist at a level below the RAR activating threshold and at or above the RXR effective dose.Type: GrantFiled: January 12, 2016Date of Patent: May 23, 2017Assignee: IO Therapeutics, Inc.Inventor: Roshantha A. Chandraratna
-
Patent number: 9630918Abstract: Cysteine, N-acetylcysteine, and penicillamine related compounds, pharmaceutical compositions comprising the cysteine, N-acetylcysteine, and penicillamine related compounds, and methods of using cysteine, N-acetylcysteine, and penicillamine related compounds and pharmaceutical compositions thereof for treating liver, kidney, lung, neurological, inflammatory, and autoimmune disorders including paracetamol overdose, non-alcoholic steatohepatitis, Wilson's disease, cystinuria, irritable bowel disorder, ulcerative colitis, rheumatoid arthritis, chronic obstructive pulmonary disease, interstitial lung disease, asthma, cystic fibrosis, Parkinson's disease, and Huntington's disease.Type: GrantFiled: September 19, 2015Date of Patent: April 25, 2017Inventor: Mark Quang Nguyen
-
Patent number: 9629835Abstract: A method for treating tau-associated disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. Particularly, a method for treating Alzheimer's disease by administering a pharmaceutical composition comprising a quinoline derivative to a subject in need is disclosed. The two disclosed quinoline derivatives have the inhibition effect for GSK-3? kinase activity, so as the two disclosed quinoline derivatives have the ability for inhibiting tau hyperphosphorylation or reducing tau aggregation.Type: GrantFiled: August 16, 2016Date of Patent: April 25, 2017Assignee: National Taiwan Normal UniversityInventors: Guey-Jen Lee-Chen, Hsiu-Mei Hsieh, Guan-Chiun Lee, Ying-Chieh Sun
-
Patent number: 9593136Abstract: In particular, the compound is effective to inhibit Dxr in Mycobacterium tuberculosis (Mtb). The present invention relates to compounds having general formula (I) or (II) where X is an acidic group, such as carboxylate, phosphonate, sulfate, and tetrazole; Ar is a substituted or unsubstituted aromatic or heteroaromatic group; and n is 0, 1, 2, 3, or 4, preferably 2, 3, or 4. The compounds inhibits 1-deoxy-D-xylulose-5-phosphate reductoisomerase (Dxr), particularly Dxr in Mycobacterium tuberculosis (Mtb).Type: GrantFiled: June 29, 2012Date of Patent: March 14, 2017Assignees: The George Washington University, George Mason University, St. Jude Children's Research Hospital, Inc., The United States of America, as Represented by the Secretary, Department of Health and Human ServicesInventors: Helena I. Boshoff, Cynthia S. Dowd, Emily R. Jackson, Kylene Kehn-Hall, Richard E. Lee, Robin Lee, Geraldine San Jose
-
Patent number: 9539303Abstract: The present invention provides compositions and methods for the treatment of /??s-expressing tumors using at least one DAC inhibitor (e.g., romidepsin).Type: GrantFiled: April 13, 2007Date of Patent: January 10, 2017Assignee: Celgene CorporationInventors: William McCulloch, Mitchell Keegan
-
Patent number: 9540373Abstract: This invention relates to a compound of formula I wherein A and Cy have one of the meanings as indicated in the specification and their use as inhibitors of Cathepsin C, pharmaceutical compositions containing the same and methods of using the same as agents for treatment and/or prevention of diseases connected with dipeptidyl peptidase I activity, e.g. respiratory diseases.Type: GrantFiled: September 10, 2015Date of Patent: January 10, 2017Assignee: Boehringer Ingelheim International GmbHInventors: Viktor Vintonyak, Matthias Grauert, Marc Grundl, Alexander Pautsch
-
Patent number: 9512065Abstract: The invention provides new polymorphs of N—[(R)-1-[(S)-1-(4-aminomethyl-benzylcarbamoyl)-2-phenyl-ethylcarbamoyl]-2-(4-ethoxy-phenyl)-ethyl]-benzamide hydrochloride, pharmaceutical compositions containing them and their use in therapy.Type: GrantFiled: July 5, 2013Date of Patent: December 6, 2016Assignee: Kalvista Pharmaceuticals LimitedInventors: Julian Scott Northen, John Mykytiuk
-
Patent number: 9452985Abstract: An object of the present invention is to provide a probe for imaging a ?-sheet structure protein which can be used for the diagnosis of conformational diseases, particularly disease (tauopathy) having a cardinal symptom such as intracerebral accumulation of tau protein, for example, Alzheimer's disease. Another object of the present invention is to provide a compound which is highly specific to tau and can image tau with satisfactory sensitivity, and also has high brain transition, low or non-recognized bone-seeking properties and low or non-recognized toxicity. According to the present invention, the above problems are solved by providing a compound of a formula I (wherein A, R1, R2, R3, R4, R5, R6, Ra and Rb are as defined in the present description) or a pharmaceutically acceptable salt or solvate thereof.Type: GrantFiled: September 22, 2015Date of Patent: September 27, 2016Assignee: GE Healthcare LimitedInventors: Yukitsuka Kudo, Shozo Furumoto, Nobuyuki Okamura
-
Patent number: 9447047Abstract: Inhibitors of protein phosphatase-1 (PP-1) and their use in a method for the treatment or prevention of viral infections caused by HIV or ebola virus are disclosed. Inhibitors of protein phosphatase-1 in effective amounts have been shown to slow down viral replication upon contacting ebola virus or cells containing the ebola virus.Type: GrantFiled: March 14, 2013Date of Patent: September 20, 2016Assignees: Howard University, The Board of Regents of the University of Texas SystemInventors: Sergei Nekhai, Alexander Bukreyev
-
Patent number: 9358227Abstract: Pharmaceutical uses of 6-amino quinazoline or 3-cyano quinoline derivatives are disclosed. Specifically, the 6-amino quinazoline or 3-cyano quinoline derivatives presented by general formula (I), or tautomers, enantiomers, diastereomers, racemates or pharmaceutically acceptable salts thereof, or metabolites, metabolic precursors or prodrugs thereof, are protein kinase inhibitors, in which each substitutent group of general formula (I) is as defined in the specification.Type: GrantFiled: December 1, 2014Date of Patent: June 7, 2016Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Xin Li, Bin Wang
-
Patent number: 9233926Abstract: Small molecule compounds and methods for stem cell differentiation are provided herein. An example of a class of compounds that may be used to practice the methods disclosed herein is represented by enantiomerically pure isomers of compounds of Formula I: or a chirally pure stereoisomer, pharmaceutically acceptable salt, or solvate thereof, wherein R1, R2, R3, R4, R5, R5?, R6, R6?, R7, R7? are as described herein.Type: GrantFiled: March 23, 2012Date of Patent: January 12, 2016Assignees: Sanford-Burnham Medical Research Institute, Human Biomolecular Research Institute, ChemRegen, Inc.Inventors: Mark Mercola, John Cashman, Marion Lanier, Erik Willems, Dennis Schade
-
Patent number: 9226901Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.Type: GrantFiled: September 25, 2013Date of Patent: January 5, 2016Assignee: LOCL Pharma, Inc.Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
-
Patent number: 9198867Abstract: Methods and compositions are provided which comprise effective amounts of analgesic to treat a subject, including reducing or eliminating an adverse effect associated with the analgesic.Type: GrantFiled: January 10, 2012Date of Patent: December 1, 2015Assignee: CHARLESTON LABORATORIES, INC.Inventors: Paul Bosse, John Ameling, Bernard Schachtel, Ray Takigiku
-
Patent number: 9162983Abstract: The present invention relates to organophosphate-inhibited acetylcholinesterase (AChE) reactivators with central nervous system (CNS) bioavailability and their associated methods of preparation including their use for treatment of exposure to AChE inhibitors such as an organophosphate (OP) insecticides and nerve agents.Type: GrantFiled: May 22, 2014Date of Patent: October 20, 2015Assignee: SOUTHWEST RESEARCH INSTITUTEInventors: William E. Bauta, William R. Cantrell, Jr., Michael W. Tidwell
-
Patent number: 9150510Abstract: The amino acid derivative of the present invention provides a novel compound that shows excellent analgesic action. The amino acid derivative of the present invention is a novel compound that shows excellent analgesic action to not only a model animal for nociceptive pains but also a model animal for neuropathic pains, so that the amino acid derivative is very useful as a drug for treating various pain diseases.Type: GrantFiled: September 17, 2009Date of Patent: October 6, 2015Assignee: NIPPON ZOKI PHARMACEUTICAL CO., LTD.Inventors: Tomohiro Ookubo, Ko Nakamura, Hiroyoshi Nanba, Hiroyuki Yoshida, Yoshitaka Nakazawa
-
Methods for the identification and treatment of patients sensitive to anti IGF-1R inhibition therapy
Patent number: 9110082Abstract: The present invention relates to methods for treating a dalotuzumab responsive cancer, in a patient, comprising determining the expression level of liver kinase B1 (LKB1), in a cancer cell from the patient, and when said expression is determined to be lower than that of a control cell; administering, to said patient, a therapeutically effective amount of dalotuzumab. The invention also relates to methods for assessing neoplastic cells, selecting patients, selecting therapies as well as diagnostic methods.Type: GrantFiled: November 22, 2010Date of Patent: August 18, 2015Assignee: MERCK SHARP & DOHME CORP.Inventors: Sriram Sathyanarayanan, Christopher Winter, Youyuan Xu -
Patent number: 9102621Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to 5 compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): 10 X NH O S O O R1 R2 R5 R4 R3 Het1 (I) or a pharmaceutically acceptable salt thereof, wherein X, Het1, R1, R2, R3, R4 and R5 are as defined in the description. 15 Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: GrantFiled: July 4, 2011Date of Patent: August 11, 2015Assignee: Pfizer LimitedInventors: Alan Daniel Brown, David James Rawson, Robert Ian Storer, Nigel Alan Swain
-
Patent number: 9102665Abstract: The present invention relates to novel cysteinyl leukotriene (specifically LTD4) antagonists, mainly to quinolin, quinoxaline or benz[c]thiazole derivatives represented by the general formula (I), or the pharmaceutically acceptable salt thereof, process of preparation thereof, and to the use of the compounds in the preparation of pharmaceutical compositions for the therapeutic treatment of disorders related to cysteinyl leukotriene, in mammals, more specially in humans.Type: GrantFiled: July 26, 2012Date of Patent: August 11, 2015Assignee: Sun Pharma Advanced Research Company Ltd.Inventors: Rajendrasinh Rathod, Tushar Bhatt, Kiritkumar Joshi, Binaka Dole, Kadiyala V. S. N. Murty, Rajamannar Thennati
-
Patent number: 9096500Abstract: The invention relates to sulfonamide derivatives, to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. More particularly the invention relates to a new sulfonamide Nav1.7 inhibitors of formula (I): or a pharmaceutically acceptable salt thereof, wherein X, Ar1, R1, R2, R3, R4 and R5 are as defined in the description. Nav 1.7 inhibitors are potentially useful in the treatment of a wide range of disorders, particularly pain.Type: GrantFiled: July 4, 2011Date of Patent: August 4, 2015Assignee: Pfizer LimitedInventors: Alan Daniel Brown, David James Rawson, Robert Ian Storer, Nigel Alan Swain
-
Publication number: 20150148301Abstract: The present invention relates to inhibitors of the activity of Complex (III) of the mitochondrial electron transport chain and use thereof in treatment and/or prevention of cancers presenting tumour-initiating cells. The present invention further relates to pharmaceutical compositions containing said inhibitors alone or in combination with other pharmaceutically active agents, and their use as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit.Type: ApplicationFiled: May 23, 2013Publication date: May 28, 2015Inventors: Virginie Clement-Schatlo, Thomas Fessard, Damien Barbaras, Joana Matos, Erick Carreira
-
Publication number: 20150148360Abstract: The present invention provides novel compounds of Formula (I), and pharmaceutically compositions thereof. Compounds of Formula (I) are inhibitors of histone deacetylases (HDACs) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase (HMGR). Also provided are methods of using the compounds and pharmaceutical compositions for inhibiting the activity of HDACs and HMGR, treating diseases associated with HDACs or HMGR (e.g., cancer, hypercholesterolemia, an acute or chronic inflammatory disease, autoimmune disease, allergic disease, pathogen infection, neurodegenerative disease, and a disease associated with oxidative stress), or inhibiting drug resistance of cancer cells.Type: ApplicationFiled: July 19, 2013Publication date: May 28, 2015Inventors: Jung-Hsin Lin, Jim-Min Fang, Ting-Rong Chen, Jhih-Bin Chen, Ching-Chow Chen, Tzu-Tang Wei
-
Publication number: 20150148376Abstract: The present application relates to novel 5-amino-5,6,7,8-tetrahydroquinoline-2-carboxylic acids, to processes for their preparation, to their use for the treatment and/or prevention of diseases, and to their use for producing medicaments for the treatment and/or prevention of diseases, especially for the treatment and/or prevention of cardiovascular and cardiopulmonary disorders.Type: ApplicationFiled: January 29, 2015Publication date: May 28, 2015Applicant: BAYER PHARMA AKTIENGESELLSCHAFTInventors: Michael HAHN, Markus Follmann, Walter Hübsch, Eva-Maria Becker, Johannes-Peter Stasch, Joerg Keldenich, Martina Delbeck, Hanna Tinel, Frank Wunder, Joachim Mittendorf, IIdiko Terebesi, Dieter Lang, René Martin
-
Publication number: 20150148318Abstract: A method of inhibiting the growth of cancer cells is disclosed in which cancer cells that contain an enhanced amount relative to non-cancerous cells of one or more of phosphorylated mTOR, Akt1, ERK2 and serine2152-phosphorylated filamin A are contacted with an FLNA-binding effective amount of a compound or a pharmaceutically acceptable salt thereof that binds to the pentapeptide of filamin A (FLNA) of SEQ ID NO: 1 and exhibits at least about 60 percent of the FITC-labeled naloxone binding amount when present at a 10 ?M concentration and using unlabeled naloxone as the control inhibitor at the same concentration. A compound that binds to the FLNA pentapeptide preferably also contains at least four of the six pharmacophores of FIGS. 19-24.Type: ApplicationFiled: September 26, 2014Publication date: May 28, 2015Inventors: Hoau-Yan Wang, Lindsay Burns Barbier
-
Patent number: 9040021Abstract: Heterocyclic compounds of formula (I) useful as imaging probes of Tau pathology in Alzheimer's disease are described. Compositions and methods of making such compounds are also described.Type: GrantFiled: November 7, 2011Date of Patent: May 26, 2015Assignee: GE Healthcare LimitedInventors: Clare Jones, Amanda Ewan, Duncan Wynn, Alessandra Gaeta, James Nairne
-
Patent number: 9040558Abstract: The invention is directed to novel substituted benzylamino quinolines, compounds comprising substituted benzylamino quinolines, methods of making substituted benzylamino quinolines, the use of substituted benzylamino quinolines for treating or preventing a variety of conditions or diseases associated with lipoprotein metabolism, and the use of substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors.Type: GrantFiled: December 28, 2005Date of Patent: May 26, 2015Assignee: DR. REDDY'S LABORATORIES LTD.Inventors: Anima Baruah, Dibyendu De, Ish Kumar Khanna, Sivaram Pillarisetti, Santanu Maitra, Christopher W. Alexander, Jennepalli Sreenu, Indu Dager, Shanavas Alikunju
-
Patent number: 9040553Abstract: The present invention provides a process for the synthesis of substituted phenoxymethylpropionic acid and related compounds. The compounds are useful for inhibiting the formation of AGEs (Advanced Glycation End Products).Type: GrantFiled: July 11, 2013Date of Patent: May 26, 2015Assignee: CELL VIABLE CORPORATIONInventors: Iraj Lalezari, Jill Fabricant
-
Publication number: 20150141415Abstract: The present invention relates to methods for treating an infectious disease in a subject in need thereof via administration of a therapeutically effective amount of compounds described herein. The methods may utilize particular compounds, for example, a quinoline, a hydrazone, a quinone, or a pyrimidine derivatives thereof or a pharmaceutical salts thereof.Type: ApplicationFiled: November 7, 2014Publication date: May 21, 2015Inventors: Omonike Arike Olaleye, Sarah Finney John, Adaugo Chimzurum Isichei, Jun O Liu, Rosa Maldonado, Janice Endsley
-
Publication number: 20150141422Abstract: Disclosed herein are new heterocyclic compounds and compositions and their application as pharmaceuticals for the treatment of disease. Methods of inhibiting PAS Kinase (PASK) activity in a human or animal subject are also provided for the treatment of diseases such as diabetes mellitus.Type: ApplicationFiled: January 26, 2015Publication date: May 21, 2015Inventors: John M. McCall, Donna L. Romero, Michael Clare
-
Patent number: 9034901Abstract: The invention provides the process for the preparation of pitavastatin and its pharmaceutically acceptable salts thereof. In particular, the invention provides a process for the preparation of stable pitavastatin calcium in crystalline form having water content less than 5% wt/wt. The present invention also provides stable crystalline form of pitavastatin calcium substantially free from crystal Form-A and use thereof for pharmaceutical compositions.Type: GrantFiled: August 24, 2011Date of Patent: May 19, 2015Assignee: Cadila Healthcare LimitedInventors: Shriprakash Dhar Dwivedi, Dhimant Jasubhai Patel, Alpesh Pravinchandra Shah, Brij Khera
-
Patent number: 9029392Abstract: Disclosed are a series of quinoline and quinoxaline derivatives comprising a fluorinated ethyl side-chain, being selective inhibitors of PI3 kinase enzymes, are accordingly of benefit in medicine, for example in the treatment of inflammatory, autoimmune, cardiovascular, neurodegenerative, metabolic, oncological, nociceptive or ophthalmic conditions.Type: GrantFiled: September 2, 2011Date of Patent: May 12, 2015Assignee: UCB Pharma S.A.Inventors: Andrew Harry Parton, Mezher Hussein Ali, Daniel Christopher Brookings, Julien Alistair Brown, Daniel James Ford, Richard Jeremy Franklin, Judi Charlotte Neuss, Joanna Rachel Quincey, Jackalyn Hinkins
-
Publication number: 20150126549Abstract: The present invention relates to the general field of the treatment and prevention of diseases involving an inflammatory condition, namely sepsis or infectious or viral diseases as well as diseases requiring for the of treatment an immunosuppressive activity namely autoimmune diseases and graft rejection. In particular, the invention relates to an inhibitor of the activity or the formation of the PP1/GADD34 complex for the treatment of a condition requiring an immunosuppressive activity or an anti-inflammatory activity.Type: ApplicationFiled: November 7, 2014Publication date: May 7, 2015Applicants: INSERM (Institut National de la Sante et de la Recherche Medicale), Universite d'Aix-MarseilleInventor: Philippe Pierre
-
Publication number: 20150126473Abstract: The present disclosure provides an isolated particle comprising very high density, ultra small, lipid depleted apo B containing particles, and may also contain cytokeratin 8. The isolated particle is useful in diagnostic assays, which are also provided.Type: ApplicationFiled: June 14, 2012Publication date: May 7, 2015Applicant: Children's Hospital & Research Center at OaklandInventors: Ronald M. Krauss, Mohmed Elfatih Ashmaig
-
Publication number: 20150126437Abstract: The disclosure provides compounds useful as insect repellents, compositions comprising such repellents, and methods of repelling an arthropod using such compounds and compositions. The disclosure further provides insect traps and method for identifying ligands and cognates for biological molecules.Type: ApplicationFiled: October 17, 2012Publication date: May 7, 2015Applicant: The Regents of the University of CaliforniaInventors: Anandasankar Ray, Sean Michael Boyle
-
Patent number: 9023848Abstract: The present invention provides compounds of formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful in treating central nervous system disorders, such as anxiety disorders or depression.Type: GrantFiled: March 2, 2012Date of Patent: May 5, 2015Assignee: Bionomics LimitedInventors: Bernard Luke Flynn, Dharam Paul, Andrew John Harvey, Damian Wojciech Grobelny, Sue O'Connor, Jonathan Bayldon Baell, Brad Sleebs, Ian Phillip Street
-
Publication number: 20150119414Abstract: A composition and a method of treatment utilizing a combination of statins (or HMG-CoA reductase inhibitors), a class of drug used to lower cholesterol levels by inhibiting the enzyme HMG-CoA reductase, with mixtures of an omega-3 fatty acid formulation containing about 90% or more omega 3 fatty acids by weight including a combination of Eicosapentaenoic acid (EPA), Docosapentaenoic acid (DPA) and Docosahexaenoic acid (DHA) in a weight ratio of EPA:DHA of from 5.7 to 6.3, wherein the sum of the EPA, DHA and DPA represent about 82% by weight of the total formulation and about 92% of the total omega 3 fatty acid content of the composition are taught.Type: ApplicationFiled: January 2, 2015Publication date: April 30, 2015Applicant: PIVOTAL THERAPEUTICS INC.Inventors: George JACKOWSKI, Rachelle MACSWEENEY, Nisar Ahmad SHAIKH, Jason YANTHA, Valerie B. SCHINI-KERTH
-
Publication number: 20150119418Abstract: Provided is a pharmaceutical agent containing a compound represented by General Formula (1), a pharmaceutically acceptable salt thereof, or a solvate thereof: wherein A represents a C1-C3 linear alkylene group, in which one methylene group is optionally substituted with O or S; n represents an integer of from 3 to 5; X1 and X2 each independently represent CH or N; W1 and W2 each independently represent a carboxyl group or a tetrazolyl group; V represents a C1-C8 linear or branched alkylene group, in which one methylene group is optionally substituted with O or S; and R represents a substituted phenyl group, for example.Type: ApplicationFiled: April 15, 2013Publication date: April 30, 2015Applicant: TOA EIYO LTD.Inventors: Kazuhiro Uemoto, Yoshimichi Sato, Naoki Okada, Emiko Iimori, Masayuki Kageyama
-
Publication number: 20150111886Abstract: The invention relates to a compound of formula (I) wherein A1, R1 and R2 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.Type: ApplicationFiled: December 22, 2014Publication date: April 23, 2015Applicant: Hoffmann-La Roche Inc.Inventors: Atsushi Kimbara, Uwe Grether, Matthias Nettekoven, Bernd Puellmann, Mark Rogers-Evans, Tanja Schulz-Gasch
-
Patent number: 9012474Abstract: The invention relates to pharmaceutical compositions comprising (i) a fluoroquinolone, (ii) a salt formed between a carboxylate anion and a divalent metal cation, (iii) a liquid comprising an organic solvent selected from the group consisting of glycerol, propylene glycol, glycerol formal, and (iv) optionally water. The invention further relates to methods of treating or preventing a condition in an animal comprising administering to the animal in need thereof a pharmaceutical composition of the invention.Type: GrantFiled: September 15, 2008Date of Patent: April 21, 2015Assignee: Idexx Laboratories Inc.Inventor: Yerramilli V. S. N. Murthy
-
Patent number: 9012496Abstract: A pharmaceutical composition comprising Compound 1, (R)-1-(2,2-difluorobenzo[d][1,3]dioxo-5-yl)-N-(1-(2,3-dihydroxypropyl)-6-fluoro-2-(1-hydroxy-2-methylpropan-2-yl)-1H-indol-5-yl)cyclopropanecarboxamide, and at least one excipient selected from: a filler, a disintegrant, a surfactant, a glidant and a lubricant, the composition being suitable for oral administration to a patient in need thereof to treat a CFTR mediated disease such as Cystic Fibrosis. Methods for treating a patient in need thereof include administering the pharmaceutical composition of Compound 1 are also disclosed.Type: GrantFiled: July 15, 2013Date of Patent: April 21, 2015Assignee: Vertex Pharmaceuticals IncorporatedInventors: Rossitza Gueorguieva Alargova, Craig Antony Dunbar, Irina Nikolaevna Kadiyala
-
Publication number: 20150104504Abstract: The present disclosure provides pharmaceutical compositions of statins and polyunsaturated fatty acids (PUFAs), in which the statins are dissolved in the PUFAs, the PUFA species being present substantially in the free acid form. Also provided are oral unit dosage forms of the disclosed pharmaceutical compositions and methods of treating blood lipid disorders using the compositions and oral unit dosage forms.Type: ApplicationFiled: May 7, 2013Publication date: April 16, 2015Inventors: Bernardus Machielse, Timothy J. Maines, Michael H. Davidson, Bharat M. Mehta
-
Publication number: 20150105372Abstract: The present invention comprises compounds of Formula I. wherein: R1, R2, R3, R4, R5, R6, R7, R8, and R9 are defined in the specification. The invention also comprises a method of treating or ameliorating a syndrome, disorder or disease, wherein said syndrome, disorder or disease is rheumatoid arthritis or psoriasis. The invention also comprises a method of modulating ROR?t activity in a mammal by administration of a therapeutically effective amount of at least one compound of claim 1.Type: ApplicationFiled: October 15, 2013Publication date: April 16, 2015Applicant: JANSSEN PHARMACEUTICA NVInventors: KRISTI A. LEONARD, KENT BARBAY, JAMES P. EDWARDS, KEVIN D. KREUTTER, DAVID A. KUMMER, UMAR MAHAROOF, RACHEL NISHIMURA, MAUD URBANSKI, HARIHARAN VENKATESAN, AIHUA WANG, RONALD L. WOLIN, CRAIG R. WOODS, ANNE FOURIE, XIAOHUA XUE, MAXWELL D. CUMMINGS
-
Publication number: 20150099015Abstract: Methods and compositions are provided for treating neuropsychiatric disorders such as schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, and bipolar disorder. The methods entail administering to a patient diagnosed as having a neuropsychiatric disorder (e.g., schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia bipolar disorder, etc.) or as at risk for a neuropsychiatric disorder a benzoic acid, benzoic acid salt, and/or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, in combination with a neuropharmacological agent (e.g., an antipsychotic, an antidepressant, medications for attention deficit and hyperactivity disorder, cognitive impairment, or dementia, etc.) where the benzoic acid, benzoic acid salt, or benzoic acid derivative, and/or a sorbic acid, sorbic acid salt, and/or sorbic acid derivative, is in an amount sufficient to increase the efficacy of the neuropharmacological agent.Type: ApplicationFiled: November 24, 2014Publication date: April 9, 2015Inventor: Guochuan Emil TSAI
-
Patent number: 8999972Abstract: The present invention provides methods and compositions comprising compounds useful for stimulating neurogenesis. The methods and compositions comprising compounds are also useful for inhibiting neuronal degeneration. Thus, the present invention can be used in the treatment of diseases and conditions characterized by neuronal loss and reduced neurogenesis including Alzheimer's disease, stroke, traumatic brain injury, and depression. This invention could also be used for research products including single agents or mixtures of agents to promote, proliferate, differentiate, or maintain neurons from stem or progenitor cells.Type: GrantFiled: September 13, 2011Date of Patent: April 7, 2015Assignee: Neuronascent, Inc.Inventor: Judith Kelleher-Andersson
-
Patent number: 9000009Abstract: Methods for improving mitochondrial function, decreasing iron accumulation, and/or decreasing oxidative stress by exposing cells or treating a subject to compounds or compositions of the general formula (I) are described that are beneficial in treating, for example, diseases and conditions such as Friedreich's ataxia, normal aging, and various neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. Furthermore, such compounds are useful as probes for identifying defects in mitochondrial metabolism, mitochondrial iron accumulation, cellular stress among other mitochondrial diseases and helping to identify compounds active in overcoming such defects.Type: GrantFiled: December 10, 2009Date of Patent: April 7, 2015Assignee: The Trustees Of The University Of PennsylvaniaInventors: Robert B. Wilson, Maria Grazia Cotticelli, Phillip A. Benedetti, Amos Smith, Jason E. Melvin, Donna M Huryn
-
Publication number: 20150094334Abstract: The present invention describes a method for the treatment of a neurological condition in a subject which comprises administering to a subject in need thereof a therapeutically effect amount of a compound of the formula or pharmaceutically acceptable salts, hydrates, or solvates thereof.Type: ApplicationFiled: October 9, 2014Publication date: April 2, 2015Applicant: PRANA BIOTECHNOLOGY LIMITEDInventors: Kevin Jeffrey BARNHAM, Elisabeth Colette Louise GAUTIER, Gaik Beng KOK, Guy KRIPPNER
-
Publication number: 20150094330Abstract: The invention provides compositions and methods for wound healing and scar reduction. The compositions and methods of the invention include at least one EP4 agonist set forth herein. Wounds and or scars that can be treated by the compositions and methods of the invention can arise from events such as surgery, trauma, disease, mechanical injury, burn, radiation, poisoning, and the like.Type: ApplicationFiled: September 26, 2014Publication date: April 2, 2015Inventors: Yariv Donde, Jeremiah H. Nguyen